← Back to Search

Yohimbine HCl for Parkinson's Disease (NAinPD Trial)

Phase < 1
Waitlist Available
Led By Nathaniel M Robbins, MD
Research Sponsored by Nathaniel M. Robbins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (supine position), after 5 minutes of head-up tilt, 60 minutes after yohimbine administration (supine position), and 5 minutes after that with repeat head-up tilt.
Awards & highlights

NAinPD Trial Summary

This trial is testing the role of the noradrenergic system in non-motor symptoms of Parkinson's disease. They will be using the drug yohimbine to study this.

NAinPD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (supine position), after 5 minutes of head-up tilt, 60 minutes after yohimbine administration (supine position), and 5 minutes after that with repeat head-up tilt.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (supine position), after 5 minutes of head-up tilt, 60 minutes after yohimbine administration (supine position), and 5 minutes after that with repeat head-up tilt. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in fatigue (measured with the self-reported Fatigue Severity Scale) in patients with Parkinson's disease with and without orthostatic hypotension (PD+OH v PD-OH)
Secondary outcome measures
Change in serum catecholamine levels (supine and orthostatic) before and after yohimbine administration
Body Weight Changes
Hypotension, Orthostatic
+6 more
Other outcome measures
Between group (PD+OH v PD-OH) change in diastolic blood pressure before and after yohimbine
Between group (PD+OH v PD-OH) change in time until pupillary redilation before and after yohimbine
Bronchial Provocation Tests
+3 more

NAinPD Trial Design

1Treatment groups
Experimental Treatment
Group I: YohimbineExperimental Treatment1 Intervention
The first visit in the study has no interventional drug. Yohimbine (5mg) is administered orally during visit two, during a head up tilt test, to manipulate the noradrenergic system to determine the association between OH and NP symptoms in those with PD. Yohimbine is not administered as a treatment in this study, but as a pharmacologic tool to study the adrenergic system.

Find a Location

Who is running the clinical trial?

Nathaniel M. RobbinsLead Sponsor
Nathaniel M Robbins, MDPrincipal InvestigatorDartmouth-Hitchcock Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants can the trial accommodate at its maximum capacity?

"Affirmative. According to information on clinicaltrials.gov, this medical research is presently recruiting participants and was originally announced on October 11th 2021 with the most recent update being February 19th 2022. 22 volunteers are sought from 1 facility for this trial ."

Answered by AI

Can new participants still join this experiment?

"Affirmative. According to clinicaltrials.gov, the investigation which was initially posted on October 11th 2021 is now searching for participants. There are 22 places available at a single centre of recruitment."

Answered by AI

Who else is applying?

What state do they live in?
Connecticut
How old are they?
65+
What site did they apply to?
Dartmouth-Hitchcock
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease
Nathaniel M. Robbins 2021. "The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04346394.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top